[ad_1]
AstraZeneca Plc said it had tested people who had been vaccinated with its Covid-19 vaccine, which showed no evidence of an increased risk of developing blood clots.
The trial involved 17 million people vaccinated in the European Union and the United Kingdom after cases of thrombosis that led some countries to temporarily suspend AstraZeneca vaccines.
Suspension of AstraZeneca vaccines
RELEVANT ITEMS
Danish and Norwegian health authorities were the first to announce that they were temporarily discontinuing the AstraZeneca vaccine, following reports of blood clots in some of those vaccinated.
The last to make this decision was Ireland, whose health authorities recommended today that the use of the AstraZeneca vaccine for the new coronavirus be suspended for precautionary reasons, following cases of thrombosis in Norway.
The National Vaccination Committee of our country in a statement indicates that there is no reason for concern about the availability of the AstraZeneca vaccine and therefore, the vaccines will continue to be administered normally.
The AstraZeneca announcement
“Careful monitoring of all available safety data from more than 17 million people vaccinated in the European Union and the UK with the AstraZeneca Covid-19 vaccine has shown that there is no evidence of an increased risk of pulmonary embolism, thrombosis deep vein or thrombosis in any defined age group, sex, lot (vaccine) or in any country ”, it is mentioned in the announcement of AstraZeneca Plc.
The World Health Organization (WHO) said on Friday there is “no reason not to use” the AstraZeneca vaccine against Covid-19 after it was suspended as a precautionary measure in European countries.
At the same time, the European Medicines Agency (EMA) announced this week that nothing indicates a risk of blood clots in people who have been vaccinated with the AstraZeneca vaccine.
Follow iefimerida.gr on Google News and be the first to know all the news
See the latest news from Greece and the world, at iefimerida.gr
